Phase 4 N=20 Treatment of Lower Extremity Spider Veins With Excel V
Telangiectasis · Spider Veins
Primary: Mean Improvement of Lower Extremity Spider Veins Based on Blinded Photo Assessments — 2.5 points on Improvement scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4 A Clinical Evaluation of the Treatment of Spider Veins on the Ankles
Spider Veins
Primary: Physician Global Assessment of Improvement in Treated Spider Veins on the Ankles — 3.7 score on a scale
N/A N=22 Clinical Evaluation of the Treatment of Spider Angioma
Spider Angioma
Primary: Physician's Global Assessment Scale for Improvement of Spider Angioma — 4.5 score on a scale
Phase 3 N=279 Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) — 2.13; 4.63; 5.68; 4.87 units on a scale — p==0.0001
Phase 3 N=117 Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Great Saphenous Vein Incompetence · Visible Varicosities
Primary: Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score) — -0.80; -1.30; -1.11 score
Phase 3 N=235 Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001
Phase 1 N=21 Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)
Varicose Veins
Primary: Weight-adjusted Polidocanol Cmax (Serum) — 584.1; 1188.7; 840.7; 1189.6 ng/mL
Phase 2 N=16 An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
Varicose Veins
Primary: Responders to Treatment, Assessed by Duplex Ultrasound — 9 participants
Phase 3 N=77 Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence
Varicose Veins
Primary: The Absolute Change From Baseline Score for the VVSymQ (Total Score) at 8 Weeks — 16.7; 30.7 units on a scale
N/A N=43 Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins
Venous Insufficiency
Primary: Primary Effectiveness Objective — 53; 66 Treated IPVs
Phase 4 N=115 Polidocanol Versus Glucose Treatment of Telangiectasia Trial
Varicose Veins · Telangiectasis
Primary: Change From Baseline in Extent of Telangiectasias — 57.24; 76.08 percent of change negative values
N/A N=112 SeCure Endovenous Laser Treatment Study
Chronic Venous Insufficiency
Primary: Acute Primary Ablation Success — 96 Veins
N/A N=27 Venclose RF Ablation System for the Treatment of IPVs
Chronic Venous Insufficiency
Primary: Safety: AEs, SAEs, ADEs, SADEs, UADEs — 0; 0; 0; 0 Events
Phase 4 N=106 Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins
Varicose Veins
Primary: Efficacy in Treating Reticular Veins by Photographs: Mean Percent Reticular Vein Disappearance Two Months After Treatment. — 95.17; 85.40 % of Reticular Veins that…
N/A N=18 Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations
Vascular Malformations · Vascular Malformation Peripheral · Venous Malformation
Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml
N/A N=25 EU Post Market Clinical Follow-Up Study of the Venclose System for Saphenous Vein Incompetence
Chronic Venous Insufficiency
Primary: Vein Occlusion Rate — 29; 0; 0 limbs
N/A N=76 Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
Phase 2 N=60 Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt
Varicose Veins
Primary: Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects — 0 participants
N/A N=242 VenaSeal Sapheon Closure System Pivotal Study (VeClose)
Great Saphenous Vein (GSV) With Venous Reflux Disease
Primary: Number of Participants With Complete Closure of the Target Vein at 3 Months — 107; 109 Participants — p=<0.0001
Phase 3 N=472 Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Superficial Vein Thrombosis
Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252
N/A N=40 Venous Insufficiency and Neuromuscular Stimulation
Chronic Venous Disease · Venous Insufficiency · Deep Venous Obstruction
Primary: Percentage Change of Haemodynamic Flow — 34.8; 62.8; 9; 14.8 % change
Phase 4 N=200 Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein
Chronic Venous Insufficiency
Primary: Percentage of Participants Without Recurrent Clinical Symptoms of an Incompetent Greater Saphenous Vein After Treatment. — 79.3; 77.5 percentage of total participants
Phase 4 N=829 Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency
Chronic Venous Insufficiency
Primary: Mean Change (Reduction) From Baseline in Volume of Reference Leg at Week 16 — 1.13; 5.78 milliliters (mL) — p=0.531
Phase 4 N=69 ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.
Venous Reflux
Primary: Pain — 0.7; 1.9 units on a scale — p=<0.0001
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
Phase 4 N=35 COMFORT: A Multicenter, Open-label, Randomized, Crossover Study
Varicose Veins
Primary: Pain — 11.3; 9.5 units on a scale
N/A N=22 REVITIVE for the Treatment of Patients With Venous Insufficiency
Venous Insufficiency · Oedema · Varicose Veins
Primary: Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV — 102.4; -9.1 percentage change — p=0.001
N/A N=68 LLLT of Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency
Trophic Ulcers · Chronic Venous Insufficiency
Primary: Number of Participants With Trophic Ulcer Healing — 11; 28 Participants
N/A N=293 The Long-term Value of Preoperative Duplex Before Surgery for Varicose Veins
Varicose Veins
Primary: Rate of Re-do Surgery — 15; 38 legs
N/A N=100 Fibered Platinum Coils vs Vascular Plugs in Pelvic Varices Embolization for the Treatment of Pelvic Congestion Syndrome
Pelvic Congestion Syndrome
Primary: Change in Pain Scale — 47; 48; 2; 2 participants — p=>0.999